Erector Spinae Plane Block for Uncomplicated Renal Colic
Launched by UNIVERSITY OF MICHIGAN · Nov 22, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new way to help manage pain from kidney stones, specifically using a method called the Erector Spinae Plane Block (ESPB). The goal is to see how effective this treatment is for relieving pain and to check for any side effects that participants might experience. The study is currently looking for participants aged 65 to 74 who have confirmed kidney stones and have received pain medication in the emergency department.
To be eligible for this trial, participants should not be pregnant or breastfeeding, have certain medical conditions, or take specific medications that could interfere with the study. If you join the trial, you can expect to receive the ESPB treatment and be monitored for its effectiveness and any possible side effects. This could be an opportunity to help improve pain management for kidney stones while contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Imaging confirmation of urolithiasis on the index encounter or prior encounter within 7 days
- • Patient received one dose of parenteral pain medication in the emergency department (ED)
- Exclusion Criteria:
- • Pregnancy or breastfeeding
- • Prisoner or incarcerated individual
- • Therapeutic anticoagulation or coagulopathy.
- • Active treatment for urinary tract infection (either acute infection or chronic therapy)
- • Prior spinal surgery in the thoracic region
- • Allergy to local anesthetic or prior local anesthetic
- • Soft tissue infection overlying the injection site
- • Positive for coronavirus
- • Inability to communicate verbally or read/write in English
- • Currently taking strong CYP1A2 inhibitor (fluvoxamine, amiodarone, fluoroquinolones, etc.)
- • Glucose-6-phosphate dehydrogenase deficiency (G6PD)
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Chris Fung
Study Chair
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials